MX2014015088A - Anticuerpos anti-tofacitinib y usos de los mismos para monitorear farmacos. - Google Patents

Anticuerpos anti-tofacitinib y usos de los mismos para monitorear farmacos.

Info

Publication number
MX2014015088A
MX2014015088A MX2014015088A MX2014015088A MX2014015088A MX 2014015088 A MX2014015088 A MX 2014015088A MX 2014015088 A MX2014015088 A MX 2014015088A MX 2014015088 A MX2014015088 A MX 2014015088A MX 2014015088 A MX2014015088 A MX 2014015088A
Authority
MX
Mexico
Prior art keywords
tofacitinib
antibodies
drug monitoring
tofacitinib antibodies
immunogenic
Prior art date
Application number
MX2014015088A
Other languages
English (en)
Inventor
Joseph Paul Ii Gardner
Victoria Yatsum Wong
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2014015088A publication Critical patent/MX2014015088A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La invención proporciona anticuerpos de tofacitinib selectivos, conjugados de tofacitinib inmunogénicos que son útiles como moléculas inmunogénicas para la generación de anticuerpos específicos para tofacitinib, junto con los métodos para medir la concentración de tofacitinib en una muestra, procesos para elaborar los anticuerpos, y ensayos y kits para utilizar los anticuerpos.
MX2014015088A 2012-06-28 2013-06-18 Anticuerpos anti-tofacitinib y usos de los mismos para monitorear farmacos. MX2014015088A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261665361P 2012-06-28 2012-06-28
PCT/IB2013/055008 WO2014001967A1 (en) 2012-06-28 2013-06-18 Anti-tofacitinib antibodies and uses thereof for drug monitoring

Publications (1)

Publication Number Publication Date
MX2014015088A true MX2014015088A (es) 2015-03-05

Family

ID=49029140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015088A MX2014015088A (es) 2012-06-28 2013-06-18 Anticuerpos anti-tofacitinib y usos de los mismos para monitorear farmacos.

Country Status (13)

Country Link
US (1) US9408922B2 (es)
EP (1) EP2866840A1 (es)
JP (1) JP2015527987A (es)
KR (1) KR20150014996A (es)
CN (1) CN104411336A (es)
AU (1) AU2013282863A1 (es)
BR (1) BR112014032916A2 (es)
CA (1) CA2873192A1 (es)
HK (1) HK1207309A1 (es)
IL (1) IL236291A0 (es)
MX (1) MX2014015088A (es)
RU (1) RU2014146707A (es)
WO (1) WO2014001967A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3347099B1 (en) * 2015-09-10 2023-10-25 Becton, Dickinson and Company Cyclophosphamide analogs for use as immunogens and assay conjugates for an immunoassay of cyclophosphamide and ifosfamide
WO2018052503A1 (en) * 2016-09-14 2018-03-22 Teneobio, Inc. Cd3 binding antibodies
CN111108214B (zh) 2017-09-21 2023-10-13 贝克顿·迪金森公司 危险污染物收集试剂盒和快速测试
CN107602569A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
JP7479385B2 (ja) 2019-01-28 2024-05-08 ベクトン・ディキンソン・アンド・カンパニー 一体化されたスワブ及び検査デバイスを有する有害汚染物質採取デバイス
AR119746A1 (es) 2019-06-14 2022-01-05 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CN116396392B (zh) * 2023-01-17 2023-10-27 珠海重链生物科技有限公司 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
GB9307491D0 (en) * 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
JP5084103B2 (ja) * 2002-07-18 2012-11-28 サイトス バイオテクノロジー アーゲー ハプテン担体抱合体およびその用法
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas

Also Published As

Publication number Publication date
KR20150014996A (ko) 2015-02-09
HK1207309A1 (en) 2016-01-29
JP2015527987A (ja) 2015-09-24
AU2013282863A1 (en) 2014-11-20
EP2866840A1 (en) 2015-05-06
IL236291A0 (en) 2015-02-26
WO2014001967A1 (en) 2014-01-03
CN104411336A (zh) 2015-03-11
US9408922B2 (en) 2016-08-09
US20150337054A1 (en) 2015-11-26
BR112014032916A2 (pt) 2017-08-01
CA2873192A1 (en) 2014-01-03
RU2014146707A (ru) 2016-08-20

Similar Documents

Publication Publication Date Title
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
MX2014015088A (es) Anticuerpos anti-tofacitinib y usos de los mismos para monitorear farmacos.
TN2015000050A1 (en) Methods of treating a tauopathy
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
NZ703581A (en) Anti-cd70 antibody drug conjugates
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
EA201300978A1 (ru) Антитела к сеа
MX2015009425A (es) Metodo rapido para la deteccion de patogenos.
GB2511221A (en) Methods and compositions for classification of samples
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
NZ799532A (en) Methods and means for the production of ig-like molecules
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
GB201202223D0 (en) Immunoassay for pyrrolidinophenones
MX353954B (es) Aptameros y metodos de diagnostico para detectar el receptor del factor de crecimiento epidermal (egf).
IN2012DE01026A (es)
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
UY33994A (es) Molécula de anticuerpo de dabigatran y derivados como antídotos anticoagulantes
MX350807B (es) Composiciones y metodos para el analisis de cancer de prostata.
MX2015004419A (es) Deteccion de analito y determinacion de concentracion de analito mediante uso de perlas magnetizables.
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
TR201902547T4 (tr) Oksi̇dati̇f stresli̇ hastalarda parati̇roi̇d hormonunun ölçüm araçlari ve yöntemleri̇
GB201202631D0 (en) Method of measuring interaction between molecules
EA201690434A1 (ru) Маркирующие соединения и их применение в анализах